Navigation Links
PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans
Date:6/2/2009

MONTEREY, Calif., June 2 /PRNewswire/ -- This month's Journal of Aerosol Medicine and Pulmonary Drug Delivery features positive Phase Ib clinical trial results for PARI Pharma's L-CsA, inhaled liposomal cyclosporine A. In May, PARI Pharma received Orphan Drug Designation from the Food and Drug Administration for L-CsA, delivered via an Investigational eFlow Nebulizer System, for the prevention and treatment of bronchiolitis obliterans, a devastating, incurable disease of the small airways affecting approximately 60,000 patients worldwide.

"PARI's encouraging results show that it is feasible and well tolerated to deposit relevant amounts of L-CsA into transplanted lungs. This has the potential to prevent and treat bronchiolitis obliterans in a more efficient way compared to current oral standard treatment. Inhaled L-CsA has a favorable drug distribution to the target sites in the lung, which should lead to lower side effects than associated with systemic cyclosporine exposure," stated Prof. Jurgen Behr, head of the Division of Respiratory Disease at the Ludwig Maximilians University, Klinikum Grosshadern, Munich, Germany.

"The long-term survival rate for lung transplant patients could be greatly improved through an effective inhaled liposomal cyclosporine therapy. Using our proprietary liposomal technology we created an inhaled formulation that is free from irritating solvents and optimized for administration via an Investigational eFlow Nebulizer System without destroying the liposome," stated Dr. Manfred Keller, executive vice president and chief scientific officer of PARI Pharma GmbH. "We had a very encouraging pre-IND meeting with the FDA, and their recent Orphan Drug Designation for L-CsA, which follows a similar designation in Europe, encourages us to move forward to solve this unmet medical need."

PARI Pharma's Phase Ib clinical trial for L-CsA studied 12 lung transplant recipients, where five patie
'/>"/>

SOURCE PARI Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
2. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
3. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
4. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
5. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
7. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
8. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
9. BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
10. Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
11. TRACON Pharmaceuticals Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... August 21, 2014 BreedIT ... Ltd., the exclusive worldwide license holder and distributor ... breeders and researchers, today is pleased to announce ... with Seach Ltd, a leading Israeli medical Cannabis ... and develop new breeds of medical Cannabis to ...
(Date:8/21/2014)... 21, 2014  AliveCor, Inc. announced today ... (FDA) has granted the company clearance for ... the most common form of cardiac arrhythmia. ... if patients are experiencing AFib through real-time ... phone based AliveCor® Heart Monitor, so physicians ...
(Date:8/21/2014)... Mass. , Aug. 21, 2014   ... AEX: PHIA) today announced it has received 510(k) ... to market its precision planning application for Transcatheter ... Philips TAVI application provides interventionalists with pre-procedural, high-precision ... The Philips TAVI planning application is available as ...
Breaking Medicine Technology:BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3
... 2011 myMatrixx®, a full-service pharmacy and ancillary medical ... Phil Walls, R.Ph., Chief Clinical & Compliance Officer, has ... The first is Health Care Heroes hosted by the ... finalist in the Medical Professional Non-Physician category. Phil will ...
... Inc. dba Discharge 1-2-3 of Schaumburg, IL, ... the 2011 Chicago Innovation Awards.  The ten winners will be ... Chicago,s Harris Theater that evening. The Chicago Innovation ... recognition of the most innovative new products or services brought ...
Cached Medicine Technology:myMatrixx's Phil Walls, R.Ph. Receives National and Regional Recognition 2Callibra, Inc. dba Discharge 1-2-3™ is Named Top 75 Nominee for 10th Annual Chicago Innovation Awards 2
(Date:8/22/2014)... August 22, 2014 Teen substance abuse ... Columbus, OH. Unfortunately, most young adults never receive the ... in the community, the new Troubled Teens Columbus helpline ... seeking to overcome their drug and alcohol dependencies ... 902-4644, teens and their parents can speak directly to ...
(Date:8/22/2014)... 2014 The rising numbers of teenage ... Over the years, countless lives have been lost due to ... in the community a new helpline was established to provide ... Northeast Ohio who are seeking to overcome their chemical dependency ... at (300) 400-2616, parents and their teens can speak immediately ...
(Date:8/22/2014)... According to the market research report "Blind ... (ACC) System Market for Passenger Cars; by Geography ... by MarketsandMarkets, classifies and defines the automotive BSD ... and value. The report highlights potential growth opportunities ... review of the market drivers, restrains, growth indicators, ...
(Date:8/21/2014)... Os-Monitor.com, an outstanding online supplier of useful ... software collection ( http://www.os-monitor.com ). In addition to ... these high end items are offered with greatly ... improving productivity, the employers pay more attention to ... and network monitoring software products are becoming more ...
(Date:8/21/2014)... Strongly influenced by their self-interest, ... there are no consequences, researchers in Georgia State ... This could imply that humans are less concerned ... researchers said. Their findings are published in the ... of unfairness is affected by their self-interest, indicating ...
Breaking Medicine News(10 mins):Health News:New Helpline in Columbus Assists Troubled Teen Find Youth Rehab 2Health News:Troubled Teens in Akron, OH Can Receive Assistance from New Helpline for Addiction Recovery 2Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 2Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 3Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 4Health News:New Employee Monitoring Software Collection Unveiled By Os-Monitor.com 2Health News:Influenced by Self-Interest, Humans Less Concerned About Inequity To Others, Researchers Find 2Health News:Influenced by Self-Interest, Humans Less Concerned About Inequity To Others, Researchers Find 3
... milks, yogurts and desserts grew by 22 per cent in ... and more aware of food intolerance and allergies. //, ... further expected to grow in the next three years. According ... over 130 new product introductions of Soya-based drinks & desserts, ...
... the difference in genes might be responsible for the ... differ in reacting to medications. //, ,The study, ... Chicago, had found that children with a variant form ... to be associated with ADHD -- responded poorly to ...
... soon begin training sex workers in the state to ... the provision of $12.7 million for the project to ... to train sex workers on an alternative employment scheme ... workers recommended that they be trained in setting up ...
... have become nearly twice as prevalent in high schools in ... of middle school students admit that drugs are used, kept ... schools where drugs are widely available are three times more ... use alcohol than their peers who attend drug-free schools., ...
... two centuries ago by a German physician, is finding ... conventional medicine still views it with scepticism. //, ... on the idea of "like cures like"., ... was prescribed to combat malaria but also caused malaria-like ...
... pointed out that city people who are more exposed to ... the greenery may be more likely to become obese than ... this interesting research were published in the latest edition of ... studies have suggested that place of residence may be associated ...
Cached Medicine News:Health News:Popularity Of Homeopathy On The Increase 2Health News:Popularity Of Homeopathy On The Increase 3Health News:Exposure To Greenery And Graffiti May Affect Obesity 2
... selecting an oxygen conserver, it's important to have ... Now allied, a name synonymous with innovative excellence, ... Liberty™, two totally automatic and value packed conservers., ... Liberty can be used 8 hours a day ...
Proven and Efficient Stand-Alone Device. Offers a choice between alternate breath and every breath delivery. This model provides every breath delivery....
Lightweight Pneumatic Conserver., ,NOTE: All models passed the ASTM PS 127-00 regulator ignition safety test....
... ,Offers an average 5:1 increase in usage ... use of a standard cannula. , ,The ... offers ambulatory oxygen patients a superior alternative to ... 2-year warranty. , ...
Medicine Products: